John Isaac, Ph.D.’s scientific interests centre on synaptic mechanisms in circuit function, and how dysfunction causes psychiatric and neurological disease. He has made a series of important contributions in the understanding of the mechanisms regulating of synaptic function during development and learning, and how these processes relate to synaptic pathology in psychiatric disease. John Isaac obtained a B.Sc. in Pharmacology and Biochemistry at the University of Southampton in 1990 and remained at Southampton for his graduate work, studying mechanisms of epilepsy with Prof. Howard Wheal. In 1994 he joined Dr. Robert Malenka’s laboratory at University of California San Francisco working on mechanisms of long-term synaptic plasticity in hippocampus and somatosensory cortex, also in close collaboration with Dr. Roger Nicoll. After completion of this postdoc, John joined Graham Collingridge’s laboratory at University of Bristol UK in 1996, where he completed a one year postdoc before establishing his own lab at Bristol. He rose up through the ranks to Professor before leaving in 2004 to set up a lab at the Intramural Program at NINDS/NIH in Bethesda, MD, USA studying mechanisms and roles of synaptic plasticity in developing cortical circuits. In 2010 he left NIH to join Eli Lilly and Company at their neuroscience research campus near Windlesham in Surrey, UK. At Lilly he led a team of labs dedicated to identifying new therapies for Alzheimer’s disease and schizophrenia. In November 2014 John joined The Wellcome Trust as Head of Neuroscience and Mental Health.